Psoriatic Arthritis (PsA) Treatment Market

By Product Type;

Nonsteriodal Anti-inflammatory Drugs [Disease Modifying Antirheumatic Drugs, Antimalarials, Methotrexate, and Others] and Corticosteriods [Biologics, TNF Inhibitors, and Interleukin Inhibitors]By Type: Oligoarticular, Polyarticular, and Others

By Administration Route;

Oral and Injectable

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Mail Order Pharmacies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa,and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn927145489 Published Date: August, 2025

Psoriatic Arthritis (PsA) Treatment Market Overview

Psoriatic Arthritis (PsA) Treatment Market (USD Million)

Psoriatic Arthritis (PsA) Treatment Market was valued at USD 10,996.12 million in the year 2024. The size of this market is expected to increase to USD 21,813.07 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.3%.


Psoriatic Arthritis (PsA) Treatment Market

*Market size in USD million

CAGR 10.3 %


Study Period2025 - 2031
Base Year2024
CAGR (%)10.3 %
Market Size (2024)USD 10,996.12 Million
Market Size (2031)USD 21,813.07 Million
Market ConcentrationLow
Report Pages339
10,996.12
2024
21,813.07
2031

Major Players

  • Pfizer Inc
  • Johnson & Johnson Services, Inc
  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Company
  • UCB S.A
  • Eli Lilly & Co
  • Novartis AG
  • Celgene Corporation
  • AstraZeneca PLC

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Psoriatic Arthritis (PsA) Treatment Market

Fragmented - Highly competitive market without dominant players


The Psoriatic Arthritis (PsA) Treatment Market is experiencing a notable surge as healthcare providers increasingly adopt targeted biologics and innovative immunosuppressants. Around 60% of providers emphasize early intervention and personalized care to reduce joint damage and enhance outcomes. This has led to greater demand for precision-based therapies, supported by heightened awareness and research-backed strategies for psoriatic arthritis management.

Tech-Driven Innovation in Therapeutics
Digital tools and biomarker-based diagnostics are playing a transformative role in the Psoriatic Arthritis (PsA) Treatment Market. Currently, over 55% of healthcare systems use these technologies to personalize treatment and track therapeutic responses. Such technological innovations are key to improving efficiency, fostering predictive approaches, and enabling the adoption of more adaptive, outcome-focused strategies.

Strategic Moves Accelerating Market Growth
To enhance market presence, over 58% of companies are turning to expansion tactics like biosimilar innovation, regional alliances, and digital platform integration. These strategies support broader access and affordability, helping companies achieve sustainable growth. The combination of commercial diversification and infrastructure development has created a solid foundation for robust expansion.

Innovation and Long-Term Potential
Looking ahead, the Psoriatic Arthritis (PsA) Treatment Market is positioned for long-term success, with nearly 62% of stakeholders investing in advanced modalities like JAK inhibitors and multi-targeted therapies. These developments promise significant gains in treatment efficacy and patient experience. As technological advancements continue to shape the landscape, the market is expected to thrive through innovation, collaboration, and forward-looking strategies.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product Type
    2. Market Snapshot, By Type
    3. Market Snapshot, By Administration Route
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Psoriatic Arthritis (PsA) Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising PsA Prevalence
        2. Growing Awareness
        3. Evolving Treatment Landscape
      2. Restraints
        1. High Treatment Costs
        2. Stringent Regulatory Requirements
      3. Opportunities
        1. Biosimilars Market Expansion
        2. Focus on Personalized Medicine
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Psoriatic Arthritis (PsA) Treatment Market, By Product Type, 2021 - 2031 (USD Million)
      1. Nonsteriodal Anti-inflammatory Drugs
        1. Disease Modifying Antirheumatic Drugs
        2. Antimalarials
        3. Methotrexate
        4. Others
      2. Corticosteriods
        1. Biologics
        2. TNF Inhibitors
        3. Interleukin Inhibitors
    2. Psoriatic Arthritis (PsA) Treatment Market, By Type, 2021 - 2031 (USD Million)
      1. Oligoarticular
      2. Polyarticular
      3. Others
    3. Psoriatic Arthritis (PsA) Treatment Market, By Administration Route, 2021 - 2031 (USD Million)
      1. Oral
      2. Injectable
    4. Psoriatic Arthritis (PsA) Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Mail Order Pharmacies
    5. Psoriatic Arthritis (PsA) Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer Inc
      2. Johnson & Johnson Services, Inc
      3. AbbVie Inc
      4. Amgen Inc
      5. Bristol-Myers Squibb Company
      6. UCB S.A
      7. Eli Lilly & Co
      8. Novartis AG
      9. Celgene Corporation
      10. AstraZeneca PLC
  7. Analyst Views
  8. Future Outlook of the Market